Triggering Receptors Expressed on Myeloid Cells 1 : Our New Partner in Human Oncology?

Inflammation is recognized as one of the hallmarks of cancer. Indeed, strong evidence indicates that chronic inflammation plays a major role in oncogenesis, promoting genome instability, epigenetic alterations, proliferation and dissemination of cancer cells. Mononuclear phagocytes (MPs) have been identified as key contributors of the inflammatory infiltrate in several solid human neoplasia, promoting angiogenesis and cancer progression. One of the most described amplifiers of MPs pro-inflammatory innate immune response is the triggering receptors expressed on myeloid cells 1 (TREM-1). Growing evidence suggests TREM-1 involvement in oncogenesis through cancer related inflammation and the surrounding tumor microenvironment. In human oncology, high levels of TREM-1 and/or its soluble form have been associated with poorer survival data in several solid malignancies, especially in hepatocellular carcinoma and lung cancer. TREM-1 should be considered as a potential biomarker in human oncology and could be used as a new therapeutic target of interest in human oncology (TREM-1 inhibitors, TREM-1 agonists). More clinical studies are urgently needed to confirm TREM-1 (and TREM family) roles in the prognosis and the treatment of human solid cancers.

[1]  J. Weiss,et al.  Tumor-Infiltrating Myeloid Cells Co-Express TREM1 and TREM2 and Elevated TREM-1 Associates With Disease Progression in Renal Cell Carcinoma , 2022, Frontiers in Oncology.

[2]  C. Print,et al.  Bulk and Single-Cell Profiling of Breast Tumors Identifies TREM-1 as a Dominant Immune Suppressive Marker Associated With Poor Outcomes , 2021, Frontiers in Oncology.

[3]  N. Jahchan,et al.  Abstract P104: Therapeutic targeting of TREM1 with PY159 promotes myeloid cell reprogramming and unleashes anti-tumor immunity , 2021, Poster Presentations - Proffered Abstracts.

[4]  Yan Wang,et al.  TREM2: Keeping Pace With Immune Checkpoint Inhibitors in Cancer Immunotherapy , 2021, Frontiers in Immunology.

[5]  A. Mebazaa,et al.  sTREM-1 is a specific biomarker of TREM-1 pathway activation , 2021, Cellular & Molecular Immunology.

[6]  Song Wu,et al.  Analysis of the Prognostic Value and Potential Molecular Mechanisms of TREM-1 Overexpression in Papillary Thyroid Cancer via Bioinformatics Methods , 2021, Frontiers in Endocrinology.

[7]  Lingling Wu,et al.  TREM-1 promoted apoptosis and inhibited autophagy in LPS-treated HK-2 cells through the NF-κB pathway , 2021, International journal of medical sciences.

[8]  V. Matejčík,et al.  TREM-1 and TREM-2 Expression on Blood Monocytes Could Help Predict Survival in High-Grade Glioma Patients , 2020, Mediators of inflammation.

[9]  F. Vandenhende,et al.  Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial , 2020, Intensive Care Medicine.

[10]  M. Bosco,et al.  Targeting Mononuclear Phagocyte Receptors in Cancer Immunotherapy: New Perspectives of the Triggering Receptor Expressed on Myeloid Cells (TREM-1) , 2020, Cancers.

[11]  A. Sigalov.  Commentary: Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation , 2020, Frontiers in Immunology.

[12]  J. Lemarié,et al.  Triggering Receptor Expressed on Myeloid Cells-1 Inhibitor Targeted to Endothelium Decreases Cell Activation , 2019, Front. Immunol..

[13]  Gregory J. Gores,et al.  A global view of hepatocellular carcinoma: trends, risk, prevention and management , 2019, Nature Reviews Gastroenterology & Hepatology.

[14]  L. Galluzzi,et al.  Macrophages and Metabolism in the Tumor Microenvironment. , 2019, Cell metabolism.

[15]  Haiyang Xie,et al.  Blocking Triggering Receptor Expressed on Myeloid Cells‐1‐Positive Tumor‐Associated Macrophages Induced by Hypoxia Reverses Immunosuppression and Anti‐Programmed Cell Death Ligand 1 Resistance in Liver Cancer , 2019, Hepatology.

[16]  Seon-Young Kim,et al.  Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer , 2019, World journal of gastroenterology.

[17]  R. Buhl,et al.  Soluble Triggering Receptor Expressed on Myeloid Cells 1 in lung cancer , 2018, Scientific Reports.

[18]  P. Lepage,et al.  TREM-1 Inhibition Restores Impaired Autophagy Activity and Reduces Colitis in Mice , 2018, Journal of Crohn's & colitis.

[19]  A. Sigalov,et al.  Novel TREM-1 Inhibitors Attenuate Tumor Growth and Prolong Survival in Experimental Pancreatic Cancer. , 2017, Molecular pharmaceutics.

[20]  M. Dessing,et al.  TREM‐1 and its potential ligands in non‐infectious diseases: from biology to clinical perspectives , 2017, Pharmacology & therapeutics.

[21]  Michael C. Schmid,et al.  Macrophages as Key Drivers of Cancer Progression and Metastasis , 2017, Mediators of inflammation.

[22]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[23]  Haitao Huang,et al.  TREM-1low is a novel characteristic for tumor-associated macrophages in lung cancer , 2016, Oncotarget.

[24]  Birgit Kasch,et al.  Next Generation , 2005, Im OP.

[25]  Y. Ben-Neriah,et al.  Inflammatory networks underlying colorectal cancer , 2016, Nature Immunology.

[26]  Q. Gao,et al.  TREM-1, an Inflammatory Modulator, is Expressed in Hepatocellular Carcinoma Cells and Significantly Promotes Tumor Progression , 2015, Annals of Surgical Oncology.

[27]  D. Agrawal,et al.  Chronic inflammation and cancer: emerging roles of triggering receptors expressed on myeloid cells , 2015, Expert review of clinical immunology.

[28]  Dong-Hyung Cho,et al.  A nineteen gene‐based risk score classifier predicts prognosis of colorectal cancer patients , 2014, Molecular oncology.

[29]  A. Sigalov.  A novel ligand-independent peptide inhibitor of TREM-1 suppresses tumor growth in human lung cancer xenografts and prolongs survival of mice with lipopolysaccharide-induced septic shock. , 2014, International immunopharmacology.

[30]  Robert M. Roman,et al.  TREM-1 Is Induced in Tumor Associated Macrophages by Cyclo-Oxygenase Pathway in Human Non-Small Cell Lung Cancer , 2014, PloS one.

[31]  Guang-xiu Lu,et al.  TREM-1 inhibition attenuates inflammation and tumor within the colon. , 2013, International immunopharmacology.

[32]  S. Qiu,et al.  Expression of TREM‐1 in hepatic stellate cells and prognostic value in hepatitis B‐related hepatocellular carcinoma , 2012, Cancer science.

[33]  Sven Diederichs,et al.  The hallmarks of cancer , 2012, RNA biology.

[34]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[35]  Alberto Mantovani,et al.  Macrophages, innate immunity and cancer: balance, tolerance, and diversity. , 2010, Current opinion in immunology.

[36]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[37]  Alberto Mantovani,et al.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.

[38]  D. McVicar,et al.  TREM and TREM-like receptors in inflammation and disease. , 2009, Current opinion in immunology.

[39]  J. Touraine,et al.  Dendritic cells dysfunction in tumour environment. , 2008, Cancer letters.

[40]  Hsuan-Yu Chen,et al.  TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. , 2008, American journal of respiratory and critical care medicine.

[41]  E. Karapanagiotou,et al.  Soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) detection in cancer patients: a prognostic marker for lung metastases from solid malignancies. , 2008, Anticancer research.

[42]  A. Mahdy,et al.  Production of Soluble Triggering Receptor Expressed on Myeloid Cells by Lipopolysaccharide-Stimulated Human Neutrophils Involves De Novo Protein Synthesis , 2006, Clinical and Vaccine Immunology.

[43]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[44]  M. Colonna,et al.  Cutting Edge: Inflammatory Responses Can Be Triggered by TREM-1, a Novel Receptor Expressed on Neutrophils and Monocytes1 , 2000, The Journal of Immunology.

[45]  P. Fisher,et al.  Autophagy and senescence: Insights from normal and cancer stem cells. , 2021, Advances in cancer research.